MATTHEW PERRONE | Delta Democrat-Times

Home

Similac Alimentum Hypoallergenic Infant Formula, imported from Puerto Rico, is for sale at a Stew Leonard's grocery store in Yonkers, New York, Friday, June 10, 2022. The FDA acknowledged Tuesday, Sept. 20, that its response to the national shortage of infant formula was slowed by delays in processing a whistleblower complaint and test samples from the nation’s largest manufacturing plant. A 10-page report from the agency offers the first formal account of the factors that led to the ongoing infant formula shortage. (AP Photo/Ted Shaffrey, File)

AP
free content

FDA concedes delays in response to baby formula shortage
By MATTHEW PERRONE - AP Health Writer
Tue,09/20/22-4:01PM , 297 Reads
WASHINGTON (AP) — The Food and Drug Administration acknowledged Tuesday that its response to the U.S.
Click Here to Read More

This 2018 photo provided by Amylyx shows the company's co-founders Joshua Cohen, left, and Justin Klee in Cambridge, Mass. on Sept. 2, 2022. A closely watched experimental drug for Lou Gehrig’s disease is getting an unusual second look from U.S. regulators on Wednesday, Sept. 7, 2022, amid intense pressure to approve the treatment for patients with the fatal illness. Patients and their families have rallied behind the drug from Amylyx Pharma, launching an aggressive lobbying campaign and enlisting members of Congress to push the Food and Drug Administration to grant approval. (Amylyx via AP, File)

AP
premium content - for subscribers only
Click to subscribe

FDA panel backs much-debated ALS drug in rare, 2nd review
By MATTHEW PERRONE - AP Health Writer
Wed,09/07/22-12:33PM , 240 Reads
WASHINGTON (AP) — A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig’s disease, a remarkable turnaround for the much-debated medication that was previously re
Click Here to Read More

Doses of the anti-viral drug Paxlovid are displayed in New York, on Monday, Aug. 1, 2022. Pfizer's COVID-19 pill may provide little benefit for younger adults, while still reducing the risk of hospitalization and death for higher-risk seniors, according to an Israeli study published Wednesday, Aug 24, 2022. (AP Photo/Stephanie Nano)

AP
premium content - for subscribers only
Click to subscribe

Study: Pfizer COVID pill showed no benefit in younger adults
By MATTHEW PERRONE - AP Health Writer
Wed,08/24/22-4:02PM , 257 Reads
WASHINGTON (AP) — Pfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Click Here to Read More

A one-month dosage of hormonal birth control pills is displayed in Sacramento, Calif., Aug. 26, 2016. A drug company is seeking U.S. approval for the first-ever birth control pill that women could buy without a prescription. The request from a French drugmaker sets up a high-stakes decision for the Food and Drug Administration amid the political fallout from the Supreme Court's recent decision overturning Roe v. Wade. (AP Photo/Rich Pedroncelli, File)

AP
registered content - login required to view
Click to register / login

Over-the-counter birth control? Drugmaker seeks FDA approval
By MATTHEW PERRONE - AP Health Writer
Mon,07/11/22-5:00AM , 381 Reads
WASHINGTON (AP) — For the first time, a pharmaceutical company has asked for permission to sell a birth control pill over the counter in the U.S.
Click Here to Read More

Subscribe to MATTHEW PERRONE